Befovacimab
Based on 1 Customer Validation
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 97.31%
- No. CAS: 2156634-62-5
- Peso molecular:142.98 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human IgG2 lambda
Human
TFPI
Befovacimab binds human TFPI with high affinity (<10 pM) via the K1 and K2 domains, inhibiting its interactions with both FXa and FVIIa and thus restoring their activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Befovacimab (5 and 20 mg/kg; intravenous and subcutaneous administration) dose‐dependent decreases in TFPI concentration and clotting time in female cynomolgus monkeys in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 lambda
ELISA, FACS, Functional assay
-
Immobilized TFPI Protein, Human (HEK293, His, HY-P77227) can bind Befovacimab. The EC50 for this effect is 7.004 ng/mL.
Chemical Information
-
No. CAS 2156634-62-5
-
Appearance Liquid
-
Peso molecular 142.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Befovacimab]
-
Synonyms
BAY 1093884
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Maria Elisa Mancuso, et al. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis. Haemophilia. 2022 Sep;28(5):702-712. [Content Brief]
[2]. Jian-Ming Gu, et al. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. AAPS J. 2017 Jul;19(4):1186-1195. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Befovacimab Related Classifications
HY-P99465 Related Classifications
Powered by Bioz